BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home » Blogs » BioWorld MedTech Perspectives

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Three clichés that make my skin crawl

July 26, 2011
By Mark McCarty
Ah, clichés. They're the stuff life is made of, eh? There's always the danger of resorting to them in my line of work. When I see them in my own copy, I feel a little like Harvey Korman's character in the Mel Brooks classic film “Blazing Saddles.” Korman's character is Hedley Lamarr (It's not Hedy, it's Hedley!!), the evil state attorney general who recoils at the use of the cliché “head them off at the pass.” “I HATE that cliché,” Lamarr said in disgust. Lamarr might have been a fictional...
Read More

FDA to small firms: Thanks but no thanks

July 22, 2011
By Mark McCarty
There's nothing like having siblings who are several years older and in their teens. You admire them for being so mature and so big. When you wanted to hang out with them, though, maybe they told you to buzz off. If you work for a firm intent on bringing a PMA device to market, FDA's insistence on a 1,000-patient post-approval study (PAS) for the Sapien transcatheter valve might have given you a bad case of deja vu because a small firm might not be able to get investors on board, even...
Read More

The runaway train: Conventional thinking about NIH funding

July 18, 2011
By Mark McCarty
In this blog, we've explored the issue of NIH funding twice. The first time, we examined the reported fiscal spending numbers (here) and the second time, we examined funding by program areas (here), but now we have the budget/deficit ceiling debate, and yet we still see examples of truly nonsensical arguments about NIH funding. Let's acknowledge at least one thing: It makes no sense to fatten the NIH basic research pipeline when we know FDA can never keep up with it. It's akin to putting up a larger water...
Read More

Top Five ways to tell if you're a med-tech geek

July 15, 2011
By Mark McCarty
We all find ourselves immersed in our work at times, but some jobs have tremendously broad appeal while others don't. For instance, lots of people want to own a vineyard, but even people who don't care for the idea like to talk about wine. In comparison, there are people like me whose heads are full of things most people don't care about. One day a few months back, I sauntered about mulling over the med-tech policy ramifications of something or other. Some time later, I noticed...
Read More

MDD's Top 10 deals (so far) of '11

July 14, 2011
By Amanda Pedersen
Now that the first half of 2011 is already in our rearview mirror, Medical Device Daily has compiled a Top 10 list of the biggest deals so far this year. Admittedly, the list was inspired by the excitement of last week’s dealmaking activity – Medtronic to spend a total of $645 million to buy Salient Surgical Technologies and PEAK Surgical and TPG Capital buying Immucor for $1.97 billion. So without further ado, here are the Top 10 deals MDD has reported on so far this year, not including any deals that closed this year but were first disclosed last year....
Read More

NLST results create huge opportunity for med-tech

July 12, 2011
By Omar Ford
Late last month, the American College of Radiology Imaging Network (ACRIN; Philadelphia) along with the National Cancer Institute’s Lung Screening Study Group released the results of the National Lung Screening Trial (NLST). The study supports the idea that CT Screening in older, heavy smokers can reduce mortality rates by 20% compared to standard chest X-rays.  Nearly 53,000 current and heavy smokers between the ages of 55 and 74 at 33 sites across the U.S. were enrolled in NLST. (See full study here) It should be pointed out however that the study results show that CT Screening in these patients turned up a high...
Read More

All Aboard: Medical Device Daily's Wayback Machine is Here

July 11, 2011
By Mark McCarty
I remember reruns of a cartoon about a character named Tooter Turtle, who was always appealing to Mr. Wizard to send him back in time for some form of jollies or other, and when the whole thing went south, Tooter would yell out, “help Mr. Wizarrrrrd!” At which point, Mr. Wizard would cluck about the futility of it all in his central European accent and bring Tooter back with the incantation, "drizzle, drazzle, druzzle, drome; time for zis one to come home." I never had any idea what that drizzle-drazzle stuff was all about, but it worked for Mr. Wizard....
Read More

Oh brother, it's Big Brother

July 8, 2011
By Mark McCarty
There is an Irish aphorism which states: "Anything that keeps a politician humble is healthy for democracy." The same might be said of bureaucrats. What sometimes strikes me as odd is that you can easily find coverage of the miscues of corporate America, but few media outlets are as punctilious about reporting on government's ill-intended moves. Here, then, are five reasons to mistrust government at least as much as device makers. Five: The Thompson Memo In 2003, this memo directed federal prosecutors to offer leniency to a corporate defendant if the defendant was willing to waive attorney-client privilege and/or willing...
Read More

J&J exits DES market

July 7, 2011
By Omar Ford
A few weeks ago, I made the mistake of going into the gym around 6 p.m. That's the time when all the body builders and athletes tend to circulate in the area. I also made the mistake of getting on the treadmill next to someone who obviously looks like he runs track for a living. After seeing him run close to 10 mph without breaking a sweat - and I was struggling to do six -  I left the gym dejected. The competition in there was just too great. How could I possibly keep up with someone who can do a mile...
Read More

When FDA and industry clash: media's prejudices

July 7, 2011
By Mark McCarty
First, just to let you know dear reader, this is a Casey Anthony-free blog posting. Those who are skeptical of the device industry in this world are legion, but there are a lot of reasons to cast the occasional baleful glance at government as well. What's interesting is how many in the media automatically assume that any clash between FDA and industry is necessarily the fault of industry. Case in point: I was at the American Diabetes Association annual scientific sessions about two weeks ago and had a conversation with another member of the press. She said more or less...
Read More
Previous 1 2 … 43 44 45 46 47 48 49 50 51 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing